Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods: Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias. Results: Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04). Conclusions: After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
Abstract
Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods: Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias. Results: Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0–10.8) months for regorafenib and 5.9 (95% CI, 3.7–8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30–0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51–1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04). Conclusions: After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.
참고문헌 (35)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Liu Z, "The trends in incidence of primary liver cancer caused by specific etiologies : results from the global burden of disease study 2016 and implications for liver cancer prevention", J Hepatol, 70, pp.674~683 (2019)
- Villanueva A, "Hepatocellular carcinoma", N Engl J Med, 380, pp.1450~1462 (2019)
- Dika IE, "Treatment options after sorafenib failure in patients with hepatocellular carcinoma", Clin Mol Hepatol, 23, pp.273~279 (2017)
- Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
- El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
- Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
- Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
- Finn RS, "Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : additional analyses from the phase III RESORCE trial", J Hepatol, 69, pp.353~358 (2018)
- Yau T, "Nivolumab in advanced hepatocellular carcinoma : sorafenib-experienced Asian cohort analysis", J Hepatol, 71, pp.543~552 (2019)
- Feng D, "Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma", Oncotarget, 8, pp.96649~96655 (2017)
- Finkelmeier F, "Feasibility and safety of nivolumab in advanced hepatocellular carcinoma : real-life experience from three German centers", J Cancer Res Clin Oncol, 145, pp.253~259 (2019)
- Ogasawara S, "Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma : a multicenter retrospective study in Japan", Invest New Drugs, 38, pp.172~180 (2020)
- Scheiner B, "Programmed cell death protein-1(PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma : efficacy and safety data from an international multicentre real-world cohort", Aliment Pharmacol Ther, 49, pp.1323~1333 (2019)
- Yoo C, "Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma", Invest New Drugs, 37, pp.567~572 (2019)
- Dip Borunda AK, "Cause of death in patients with hepatocellular carcinoma(HCC)according to Barcelona Clinic Liver Cancer System(BCLC) : Tumor versus nontumor-related mortality", J Clin Oncol, 29(15_suppl), pp.e14594~ (2011)
- Giannini EG, "Prognosis of untreated hepatocellular carcinoma", Hepatology, 61, pp.184~190 (2015)
- Shiba S, "Outcome and cause of death of hepatocellular carcinoma patients with extrahepatic metastases", J Clin Oncol, 33, pp.456~ (2015)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population", Hepatology, 66, pp.1454~1463 (2017)
- Lee JH, "Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria", Ann Surg, 263, pp.842~850 (2016)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Curtis LH, "Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases", Med Care, 45(10Suppl 2), pp.S103~S107 (2007)
- Rosenbaum PR, "The central role of the propensity score in observational studies for causal effects", Biometrika, 70, pp.41~55 (1983)
- Kambhampati S, "Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis : safety and clinical outcomes in a retrospective case series", Cancer, 125, pp.3234~3241 (2019)
- Ikeda M, "A phase 1b trial of lenvatinib(LEN)plus pembrolizumab(PEM)in patients(pts)with unresectable hepatocellular carcinoma(uHCC)", J Clin Oncol, 36(15_suppl), pp.4076~ (2018)
- Pishvaian MJ, "LBA26 updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma(HCC)", Ann Oncol, 29(Suppl 8), pp.viii718~viii719 (2018)
- Uchikawa S, "Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice", Hepatol Res, 48, pp.814~820 (2018)
- Jae Seung Lee, "A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea", Clinical and Molecular Hepatology, 26(1), pp.24~32 (2020), 대한간학회
- 이혜원, "Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation", Gut and Liver, 11(5), pp.693~701 (2017), 거트앤리버 소화기연관학회협의회
- Rao N, "Nivolumab for hepatocellular carcinoma(HCC)in a real-world context", J Clin Oncol, 37(15_suppl), pp.e15675~ (2019)
- Borcoman E, "Patterns of response and progression to immunotherapy", Am Soc Clin Oncol Educ Book, 38, pp.169~178 (2018)
- Grierson P, "Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab : a case report of late response after pseudoprogression", Hepatol Commun, 2, pp.148~151 (2017)
- Mamdani H, "Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma : case report and review of literature", Discov Med, 23, pp.331~336 (2017)
- Seymour L, "iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics", Lancet Oncol, 18, pp.e143~e152 (2017)